Does the media refer more to OGN or ASND?

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Organon & Co.. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 6 mentions for Organon & Co.. Ascendis Pharma A/S's average media sentiment score of 1.16 beat Organon & Co.'s score of 0.32 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AXSM or OGN?

In the previous week, Axsome Therapeutics had 3 more articles in the media than Organon & Co.. MarketBeat recorded 9 mentions for Axsome Therapeutics and 6 mentions for Organon & Co.. Axsome Therapeutics' average media sentiment score of 1.01 beat Organon & Co.'s score of 0.32 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, OGN or BBIO?

Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organon & Co. $6.22B 0.57 $187M $0.93 14.46 BridgeBio Pharma $579.96M 23.18 -$724.93M -$3.74 N/A

Does the media favor OGN or BBIO?

In the previous week, BridgeBio Pharma had 7 more articles in the media than Organon & Co.. MarketBeat recorded 13 mentions for BridgeBio Pharma and 6 mentions for Organon & Co.. BridgeBio Pharma's average media sentiment score of 0.86 beat Organon & Co.'s score of 0.32 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organon & Co. 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELAN or OGN?

In the previous week, Elanco Animal Health had 1 more articles in the media than Organon & Co.. MarketBeat recorded 7 mentions for Elanco Animal Health and 6 mentions for Organon & Co.. Elanco Animal Health's average media sentiment score of 0.88 beat Organon & Co.'s score of 0.32 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer OGN or RDY?

Organon & Co. presently has a consensus price target of $11.40, indicating a potential downside of 15.24%. Given Organon & Co.'s stronger consensus rating and higher possible upside, equities analysts plainly believe Organon & Co. is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organon & Co. 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Organon & Co. (OGN) Competitors

$13.45 +0.05 (+0.37%)

As of 03:58 PM Eastern

Compare

OGN vs. ASND, AXSM, BBIO, ELAN, and RDY

Should you buy Organon & Co. stock or one of its competitors? MarketBeat compares Organon & Co. with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Organon & Co. include Ascendis Pharma A/S (ASND), Axsome Therapeutics (AXSM), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does Organon & Co. compare to Ascendis Pharma A/S?

Organon & Co. (NYSE:OGN) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Organon & Co. has higher revenue and earnings than Ascendis Pharma A/S. Organon & Co. is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.46
Ascendis Pharma A/S	$865.78M	17.19	-$258M	$8.67	27.52

Ascendis Pharma A/S has a net margin of 57.87% compared to Organon & Co.'s net margin of 3.99%. Organon & Co.'s return on equity of 99.95% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Organon & Co. currently has a consensus target price of $11.40, indicating a potential downside of 15.24%. Ascendis Pharma A/S has a consensus target price of $295.39, indicating a potential upside of 23.81%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

77.4% of Organon & Co. shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Organon & Co. has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than Organon & Co.. MarketBeat recorded 10 mentions for Ascendis Pharma A/S and 6 mentions for Organon & Co.. Ascendis Pharma A/S's average media sentiment score of 1.16 beat Organon & Co.'s score of 0.32 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Organon & Co. on 11 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

In the previous week, Axsome Therapeutics had 3 more articles in the media than Organon & Co.. MarketBeat recorded 9 mentions for Axsome Therapeutics and 6 mentions for Organon & Co.. Axsome Therapeutics' average media sentiment score of 1.01 beat Organon & Co.'s score of 0.32 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Organon & Co. has a net margin of 3.99% compared to Axsome Therapeutics' net margin of -26.59%. Organon & Co.'s return on equity of 99.95% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Organon & Co.	3.99%	99.95%	6.22%

Axsome Therapeutics currently has a consensus target price of $258.95, suggesting a potential upside of 7.02%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 15.24%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Axsome Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

Organon & Co. has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$708.24M	17.58	-$183.17M	-$3.73	N/A
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.46

Summary

Axsome Therapeutics beats Organon & Co. on 9 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to BridgeBio Pharma?

Organon & Co. (NYSE:OGN) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Organon & Co. presently has a consensus target price of $11.40, suggesting a potential downside of 15.24%. BridgeBio Pharma has a consensus target price of $91.05, suggesting a potential upside of 32.66%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84

Organon & Co. has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.46
BridgeBio Pharma	$579.96M	23.18	-$724.93M	-$3.74	N/A

In the previous week, BridgeBio Pharma had 7 more articles in the media than Organon & Co.. MarketBeat recorded 13 mentions for BridgeBio Pharma and 6 mentions for Organon & Co.. BridgeBio Pharma's average media sentiment score of 0.86 beat Organon & Co.'s score of 0.32 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organon & Co.	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Organon & Co. has a net margin of 3.99% compared to BridgeBio Pharma's net margin of -124.42%. Organon & Co.'s return on equity of 99.95% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Summary

Organon & Co. and BridgeBio Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Organon & Co. compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Organon & Co. has a net margin of 3.99% compared to Elanco Animal Health's net margin of -4.95%. Organon & Co.'s return on equity of 99.95% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Organon & Co.	3.99%	99.95%	6.22%

Elanco Animal Health currently has a consensus target price of $28.55, indicating a potential upside of 22.99%. Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 15.24%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts clearly believe Elanco Animal Health is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 1.6% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Organon & Co. has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.89B	2.37	-$232M	-$0.50	N/A
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.46

In the previous week, Elanco Animal Health had 1 more articles in the media than Organon & Co.. MarketBeat recorded 7 mentions for Elanco Animal Health and 6 mentions for Organon & Co.. Elanco Animal Health's average media sentiment score of 0.88 beat Organon & Co.'s score of 0.32 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elanco Animal Health has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

Summary

Elanco Animal Health beats Organon & Co. on 9 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Organon & Co. (NYSE:OGN) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Dr. Reddy's Laboratories has lower revenue, but higher earnings than Organon & Co.. Organon & Co. is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.46
Dr. Reddy's Laboratories	$3.58B	3.33	$456M	$0.58	24.62

Organon & Co. presently has a consensus price target of $11.40, indicating a potential downside of 15.24%. Given Organon & Co.'s stronger consensus rating and higher possible upside, equities analysts plainly believe Organon & Co. is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Organon & Co. had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 6 mentions for Organon & Co. and 0 mentions for Dr. Reddy's Laboratories. Organon & Co.'s average media sentiment score of 0.32 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Organon & Co. is being referred to more favorably in the media.

Company	Overall Sentiment
Organon & Co.	Neutral
Dr. Reddy's Laboratories	Neutral

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Organon & Co.'s net margin of 3.99%. Organon & Co.'s return on equity of 99.95% beat Dr. Reddy's Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.99%	99.95%	6.22%
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%

Organon & Co. has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Dr. Reddy's Laboratories pays an annual dividend of $0.07 per share and has a dividend yield of 0.5%. Organon & Co. pays out 8.6% of its earnings in the form of a dividend. Dr. Reddy's Laboratories pays out 12.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Organon & Co. is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Organon & Co. beats Dr. Reddy's Laboratories on 11 of the 17 factors compared between the two stocks.

Get Organon & Co. News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OGN vs. The Competition

Export

Metric	Organon & Co.	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$3.53B	$8.67B	$6.47B	$23.13B
Dividend Yield	0.60%	1.73%	2.68%	4.06%
P/E Ratio	14.46	23.42	24.71	31.08
Price / Sales	0.57	16.79	519.55	20.72
Price / Cash	2.32	13.96	27.92	18.65
Price / Book	4.65	6.21	10.82	4.65
Net Income	$187M	$174.80M	$3.56B	$1.07B
7 Day Performance	0.19%	2.04%	1.68%	-1.05%
1 Month Performance	0.11%	1.56%	0.44%	0.18%
1 Year Performance	36.97%	10.31%	32.84%	24.24%

Organon & Co. Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OGN Organon & Co.	2.6746 of 5 stars	$13.45 +0.4%	$11.40 -15.2%	+37.2%	$3.53B	$6.22B	14.46	10,000	News Coverage
ASND Ascendis Pharma A/S	4.9303 of 5 stars	$223.29 +2.4%	$295.39 +32.3%	+28.9%	$13.60B	$814.57M	25.75	1,189	Positive News Analyst Downgrade
AXSM Axsome Therapeutics	2.5223 of 5 stars	$253.40 -0.7%	$256.79 +1.3%	+146.2%	$13.13B	$638.50M	N/A	380	Positive News
BBIO BridgeBio Pharma	3.4989 of 5 stars	$68.00 +1.8%	$89.59 +31.8%	+65.2%	$13.08B	$502.08M	N/A	400	Positive News
ELAN Elanco Animal Health	4.1078 of 5 stars	$24.24 +0.3%	$28.20 +16.3%	+77.6%	$12.07B	$4.72B	N/A	9,400	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:OGN) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organon & Co. (OGN) Competitors

OGN vs. ASND, AXSM, BBIO, ELAN, and RDY

How does Organon & Co. compare to Ascendis Pharma A/S?

Summary

How does Organon & Co. compare to Axsome Therapeutics?

Summary

How does Organon & Co. compare to BridgeBio Pharma?

Summary

How does Organon & Co. compare to Elanco Animal Health?

Summary

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN vs. The Competition

Organon & Co. Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organon & Co. (OGN) Competitors

OGN vs. ASND, AXSM, BBIO, ELAN, and RDY

How does Organon & Co. compare to Ascendis Pharma A/S?

Which has better valuation & earnings, OGN or ASND?

Is OGN or ASND more profitable?

Do analysts prefer OGN or ASND?

Do institutionals & insiders have more ownership in OGN or ASND?

Which has more volatility and risk, OGN or ASND?

Does the media refer more to OGN or ASND?

Summary

How does Organon & Co. compare to Axsome Therapeutics?

Does the media favor AXSM or OGN?

Do insiders & institutionals hold more shares of AXSM or OGN?

Is AXSM or OGN more profitable?

Do analysts prefer AXSM or OGN?

Which has more risk & volatility, AXSM or OGN?

Which has stronger valuation and earnings, AXSM or OGN?

Summary

How does Organon & Co. compare to BridgeBio Pharma?

Do analysts rate OGN or BBIO?

Which has better earnings & valuation, OGN or BBIO?

Does the media favor OGN or BBIO?

Which has more risk and volatility, OGN or BBIO?

Do insiders and institutionals hold more shares of OGN or BBIO?

Is OGN or BBIO more profitable?

Summary

How does Organon & Co. compare to Elanco Animal Health?

Is ELAN or OGN more profitable?

Do analysts recommend ELAN or OGN?

Do institutionals & insiders believe in ELAN or OGN?

Which has better earnings & valuation, ELAN or OGN?

Does the media prefer ELAN or OGN?

Which has more volatility & risk, ELAN or OGN?

Summary

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Which has higher valuation & earnings, OGN or RDY?

Do analysts prefer OGN or RDY?

Does the media prefer OGN or RDY?

Do institutionals and insiders believe in OGN or RDY?

Is OGN or RDY more profitable?

Which has more volatility & risk, OGN or RDY?

Is OGN or RDY a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN vs. The Competition

Organon & Co. Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools